{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Laboratory values included hematology, chemistry, and urinalysis as interpreted by the investigator.","groups":[{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG000","title":"Part 3 (Dose Extension): Modakafusp Alfa 120 mg"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG001","title":"Part 3 (Dose Extension): Modakafusp Alfa 240 mg"}],"populationDescription":"FAS:all participants who took ≥1 dose,even if incomplete,of TAK-573 in Part 3 extension cohorts.However,clinically significant laboratory values data were not collected\\&will never be available to present due to issue with report form used for data collection(identified after trial completion).Assessments of clinical significance were not included in report form,making data collection impossible.This issue did not impact participant safety/reliability of study data,particularly primary endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 20.5 months in Part 3","title":"Part 3: Percentage of Participants With Clinically Significant Laboratory Values","type":"SECONDARY"}